Zyrtec Launch Brings Big Boost To Johnson & Johnson, But Competition Grows

Johnson & Johnson's OTC sales jumped 27 percent to $1.6 billion in the firm's first earnings period with allergy medication Zyrtec (cetirizine 5 mg) available over the counter, according to J&J

More from Archive

More from HBW Insight